Together, our findings demonstrate the tightly regulated interconnection between de novo lipid synthesis and CD36-mediated lipid uptake in CRC progression during targeted inhibition of FASN, suggesting that inhibition of CD36 may be necessary to improve the efficacy of FASN-targeted therapy. This evidence concerns the gene CD36 and colorectal carcinoma.